TuHURA’s new VISTA patent reaches beyond cancer, but can TBS-2025 overcome leukemia treatment resistance?
TuHURA has secured a US patent covering TBS-2025 and related VISTA-targeting antibody designs through February 2042. The intellectual property expansion follows FDA clearance of an early-stage AML study, but clinical efficacy and commercialization remain unproven.